Greg Gould, Interim President and Chief Executive Officer and Chief Financial Officer commented, "SeraCare's commitment to providing vital products and services of the highest quality has driven our growth and diversification across a blue chip life sciences customer base. Linden is a natural strategic fit for SeraCare with a proven record of operating successful companies in the healthcare and life sciences sectors. Linden's acquisition of SeraCare recognizes our accomplishments and translates them into significant value for our shareholders."
"SeraCare's product offerings, services and strong customer base provide an attractive foundation on which to compete and grow in the global high-growth markets of human diagnostics and therapeutics research and development," said Fran Lunger, a Linden Operating Partner and former CEO of Millipore Corporation.
A special meeting of SeraCare's shareholders will be held after the preparation and filing of a proxy statement with the Securities and Exchange Commission and subsequent mailing to shareholders. If the merger is approved by shareholders, the transaction is expected to close in the second quarter of calendar year 2012. The transaction is subject to various closing conditions, including the receipt of regulatory approvals, but is not subject to a financing condition. Upon completion of the acquisition, SeraCare will become a private company, wholly owned by an affiliate of Linden.
Lazard is acting as exclusive financial advisor to SeraCare and has provided a fairness opinion to the SeraCare Board of Directors. Foley Hoag LLP is serving as SeraCare's outside counsel. William Blair & Company, L.L.C. is acting as Linden's financial advisor, and Kirkland & Ellis LLP is serving as legal counsel to Linden.